UNH jumps 7% as UnitedHealth's earnings beat silences cost fears

UNH jumps 7% as UnitedHealth's earnings beat silences cost fears
Devesh Kumar
21 Apr 2026, 12:23 PM

powered by

Invezz
UNH buy

Buy UnitedHealth Group (UNH). The earnings beat wasn’t just EPS—medical care ratio (MCR) came in below feared levels, operating margin improved (6.6% vs 6.2%), and full-year adjusted EPS guidance was lifted (> $18.25 vs $17.75). The CMS finalized a 2.48% Medicare Advantage payment rate increase for 2027, removing a major planning overhang. UNH is repricing risk: cost trend control + better MA funding = multiple compression risk fading.

Key Risk: A renewed spike in medical cost trend (MCR re-accelerates) that forces guidance cuts despite the CMS rate.

Managed-care basket sell/avoid

Sell/avoid Humana (HUM) and trim Centene (CNC). The news is sector-specific: UNH’s MCR inflection and MA rate clarity are a relative advantage. If the market is rotating toward “cost-control winners,” peers with weaker margin trajectory or less credible contract repricing will underperform on any incremental cost scare.

Key Risk: Peers report similar MCR improvement or receive offsetting MA rate/contract tailwinds that narrow the relative gap.

  • Q1 earnings beat expectations on revenue, EPS and cash flow.
  • Medical care ratio comes in better than feared, signaling cost control.
  • Stock rallies as investors unwind worst-case cost assumptions.

UnitedHealth Group reported stronger-than-expected quarterly results on Tuesday, easing investor concerns that rising medical costs would weigh further on its earnings.

Shares in the US's largest private health insurer surged roughly 7% after the company posted first-quarter results that beat analyst estimates on both the top and bottom lines.

UNH rally on earnings beat

The backdrop to Tuesday's numbers matters.

UNH has shed more than 45% of its value over the past year, making it one of the most heavily punished large-cap stocks in the US market.

The pressures were both real and compounding. Medical costs had surged well ahead of premium growth, squeezing margins.

At the same time, the company was dealing with the fallout from the December 2024 killing of CEO Brian Thompson and a regulatory investigation into its billing practices.

Adding to the strain, UnitedHealth also made a deliberate move to exit underpriced Medicare Advantage contracts, shedding more than three million members in the process.

Investors heading into Tuesday were braced for another disappointment.

Instead, UnitedHealth reported adjusted earnings per share of $7.23, comfortably ahead of the consensus estimate of $6.76.

Revenue came in at $111.7 billion, topping expectations of $109.57 billion.

Cash flows from operations reached $8.9 billion, or 1.4 times net income, a number that speaks to the underlying health of the business.

The full-year adjusted EPS guidance was lifted to more than $18.25, up from a previous target of $17.75.

MCR drives UnitedHealth rally

For those outside the managed care sector, one number explains Tuesday's reaction better than any other: the medical care ratio.

It is simply the share of every premium dollar that gets paid out in patient claims. The lower it is, the more the insurer retains.

Heading into this earnings season, analysts at Zacks had pencilled in a first-quarter MCR as high as 85.7%.

When the actual figure came in below that level, investors treated it as a genuine inflection point.

UnitedHealth has spent the past several quarters repricing contracts, cutting unprofitable Medicare Advantage plans and deploying AI-driven efficiency tools to bring cost trends back under control.

Tuesday's MCR suggests those efforts are beginning to take hold.

Operating margin improved to 6.6% from 6.2% in the same period a year earlier, a modest shift, but carries an outsized signal at a company generating over $100 billion in quarterly revenue.

Management described costs as "elevated but in line with expectations," and at a company this size, meeting expectations is the whole story.

Medicare boost eases UNH outlook

One significant headwind has also cleared.

On 6 April, the Centres for Medicare and Medicaid Services finalised a 2.48% average payment rate increase for Medicare Advantage plans in 2027, equivalent to more than $13 billion in additional sector-wide funding.

That was a decisive upgrade from January's near-flat proposal of just 0.09%, which had rattled managed care stocks for months.

For UnitedHealth, the finalised rate removes one of the most persistent uncertainties over its 2027 planning cycle.